Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer’s Therapeutics

Abstract

Aging-associated neurodegenerative diseases, which are characterized by progressive neuronal death and synapses loss in human brain, are rapidly growing affecting millions of people globally. Alzheimer’s is the most common neurodegenerative disease and it can be caused by genetic and environmental risk factors. This review describes the amyloid-β and Tau hypotheses leading to amyloid plaques and neurofibrillary tangles, respectively which are the predominant pathways for the development of anti-Alzheimer’s small molecule inhibitors. The function and structure of the druggable targets of these two pathways including β-secretase, γ-secretase, and Tau are discussed in this review article. Computer-Aided Drug Design including computational structure-based design and ligand-based design have been employed successfully to develop inhibitors for biomolecular targets involved in Alzheimer’s. The application of computational molecular modeling for the discovery of small molecule inhibitors and modulators for β-secretase and γ-secretase is summarized. Examples of computational approaches employed for the development of anti-amyloid aggregation and anti-Tau phosphorylation, proteolysis and aggregation inhibitors are also reported.

Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases

“…There is a clear and unmet clinical need to develop new therapies based on understanding the molecular pathologies. One of the most promising approaches is to develop novel therapeutics using computer-aided drug design (CADD) [ 7 , 8 ].…”

In Silico Study of Centella asiatica Active Compound as BACE1 Inhibitor in Alzheimer’s Disease

“…It is known that BACE1 active site is large consisting of subsites called pockets. There are S1 pocket which has close proximity with S3 are hydrophobic region composed of Leu30, Phe108, Ile110, Ile118, and Trp115 residues; the S2 and S4 are site exposed to hydrophilic residues such as Lys9, Ser10, Thr72, Gln73, Thr231, Thr232, Arg235, Arg307, and Lys321; the S3' and S4' composed of Pro70, Thr72, Glu125 Arg128, Arg195, and Trp197 residues; then next to S4' are S2' subsites which composed of hydrophobic and amphipathic residues such as Ser35, Val69, Tyr71, Ile126, and Tyr198; also the center of the active site, the S1' subsite, contains the catalytic dyad of Asp32/Asp238 and two hydrophobic residues of Ile226 and Val 332 [10].…”

Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms

“…Processing of APP yields multiple forms of the protein; the 40 and 42 amino acid residue products are the most common forms ( O’Brien and Wong, 2011 ). High levels of monomeric amyloid β-protein have a propensity to aggregate into fibrils and then plaques, resulting in neurodegeneration and induction of tau pathology ( Mouchlis et al, 2020 ).…”